WO2013071365A1 - Procédé de traitement et de prophylaxie, et compositions utiles associées - Google Patents

Procédé de traitement et de prophylaxie, et compositions utiles associées Download PDF

Info

Publication number
WO2013071365A1
WO2013071365A1 PCT/AU2012/001422 AU2012001422W WO2013071365A1 WO 2013071365 A1 WO2013071365 A1 WO 2013071365A1 AU 2012001422 W AU2012001422 W AU 2012001422W WO 2013071365 A1 WO2013071365 A1 WO 2013071365A1
Authority
WO
WIPO (PCT)
Prior art keywords
griseofulvin
plasmodium
nmpp
effective amount
subject
Prior art date
Application number
PCT/AU2012/001422
Other languages
English (en)
Inventor
Simon James Foote
Brendan John MCMORRAN
Clare Margaret SMITH
Original Assignee
Macquarie University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macquarie University filed Critical Macquarie University
Publication of WO2013071365A1 publication Critical patent/WO2013071365A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La présente invention concerne un procédé de traitement ou de prophylaxie pour un sujet infecté par un membre du phylum des Apicomplexa ou un sujet qui a été exposé au dit membre, ledit procédé comprenant l'administration au dit sujet d'une quantité efficace de griséofulvine ou de N-méthyl protoporphyrine (NMPP).
PCT/AU2012/001422 2011-11-16 2012-11-16 Procédé de traitement et de prophylaxie, et compositions utiles associées WO2013071365A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161560497P 2011-11-16 2011-11-16
US61/560,497 2011-11-16

Publications (1)

Publication Number Publication Date
WO2013071365A1 true WO2013071365A1 (fr) 2013-05-23

Family

ID=48428845

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2012/001422 WO2013071365A1 (fr) 2011-11-16 2012-11-16 Procédé de traitement et de prophylaxie, et compositions utiles associées

Country Status (1)

Country Link
WO (1) WO2013071365A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022107161A1 (fr) * 2020-11-23 2022-05-27 Institute Of Life Sciences Griséofulvine utilisée comme médicament d'appoint pour le traitement des paludismes cérébral et grave

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004233565B2 (en) * 2003-05-02 2009-10-01 Makhteshim Chemical Works Ltd. Active substance combinations that have nematicidal, insecticidal, and fungicidal properties and are based on trifluorobutenyl compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004233565B2 (en) * 2003-05-02 2009-10-01 Makhteshim Chemical Works Ltd. Active substance combinations that have nematicidal, insecticidal, and fungicidal properties and are based on trifluorobutenyl compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NAGARAJ V. ET AL.: "Mitochondrial localization of functional ferrochelatase from Plasmodium falciparum", MOLECULAR AND BIOCHEMICAL PARASITOLOGY, vol. 168, 2009, pages 109 - 112, XP026496717 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022107161A1 (fr) * 2020-11-23 2022-05-27 Institute Of Life Sciences Griséofulvine utilisée comme médicament d'appoint pour le traitement des paludismes cérébral et grave
GB2616213A (en) * 2020-11-23 2023-08-30 Inst Of Life Sciences Griseofulvin as an adjunct drug for the treatment of cerebral and severe malaria

Similar Documents

Publication Publication Date Title
Mikolajczak et al. Plasmodium vivax liver stage development and hypnozoite persistence in human liver-chimeric mice
Croft et al. Review of pyronaridine anti-malarial properties and product characteristics
Pradel et al. Antibiotics in malaria therapy and their effect on the parasite apicoplast
Grewal Pharmacology of 8-aminoquinolines
Mukherjee et al. A phosphoinositide-binding protein acts in the trafficking pathway of hemoglobin in the malaria parasite Plasmodium falciparum
WO2007023370A1 (fr) Compositions et methodes permettant de traiter le paludisme
US11135231B2 (en) Methods and compositions for prevention and treatment of Apicomplexan infections
He et al. Antiretroviral protease inhibitors potentiate chloroquine antimalarial activity in malaria parasites by regulating intracellular glutathione metabolism
EP1768669B1 (fr) Compositions pharmaceutiques pour le traitement de la leishmaniose
WO2013071365A1 (fr) Procédé de traitement et de prophylaxie, et compositions utiles associées
US6194421B1 (en) Inhibitors of metazoan parasite proteases
Renar et al. Understanding malarial toxins
Sudhakar et al. Bazedoxifene, a postmenopausal drug, acts as an antimalarial and inhibits hemozoin formation
US20130022612A1 (en) Methods and compositions for malaria prophylaxis
Yamamoto et al. Antimalarial activity of vitamin D3 (VD3) does not result from VD3-induced antimicrobial agents including nitric oxide or cathelicidin
EP2070522A1 (fr) Composés et procédés pour prévenir et traiter les infections par Plasmodium
Sowunmi et al. Early changes in Plasmodium falciparum asexual and sexual populations in children with acute infections following treatment with artemisinin-based combination drugs
US20080119483A1 (en) Compositions and methods for inhibiting protozoan growth
US5863716A (en) Treatment of plasmodium
US11485714B2 (en) Hydroxyethylamine-based piperazine compounds, and methods of producing and using the same for treating disease
Khan et al. Molecular mechanisms of action and resistance of antimalarial drugs
WO1996009405A1 (fr) Traitement contre les parasites du genre plasmodium
Ty Oxidative Stress Primes Macrophages for Plasmodium Inflammasome Activation
US20240009165A1 (en) Griseofulvin as an adjunct drug for the treatment of cerebral and severe malaria
Nandal et al. Recent advances, challenges and updates on the development of therapeutics for malaria

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12849725

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WPC Withdrawal of priority claims after completion of the technical preparations for international publication

Ref document number: 61/560,497

Country of ref document: US

Date of ref document: 20140508

Free format text: WITHDRAWN AFTER TECHNICAL PREPARATION FINISHED

122 Ep: pct application non-entry in european phase

Ref document number: 12849725

Country of ref document: EP

Kind code of ref document: A1